Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized mRNA Tumor Vaccine in Advanced GI Cancers
NCT03468244Phase 1Unknown
- Sponsor
- Changhai Hospital
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Stemirna personalized mRNA tumor vaccine in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, pancreatic adenocarcinoma (PDAC) and 1 more, sponsored by Changhai Hospital. Primary endpoints: Number of participants with treatment-related adverse events at 24 weeks and Cytokinetics of the personalized mRNA tumor vaccine at 24 weeks. Status: unknown.
02
Drugs
Stemirna personalized mRNA tumor vaccine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomapancreatic adenocarcinoma (PDAC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT03468244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468244.